A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.
A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.
复制标题
DOI：
10.2174/1570159x13666150307004545
复制
发表时间：
2015
影响因子：
5.3
通讯作者：
Harvey BH
中科院分区：
文献类型：
--
作者：
Brand SJ;Moller M;Harvey BH
尽管为了了解情绪（抑郁症、双相情感障碍）和精神障碍的神经生物学基础进行了大量研究工作，但这些疾病的诊断和治疗评估仍然仅基于相对主观的症状评估以及心理测量评估。因此，迫切需要旨在改善当前精神病和情绪相关疾病分类的生物标志物，并使患者能够在生物学基础上分为更同质的临床不同亚组。通过识别准确反映这些疾病的病理生理过程的生物标志物可以促进这一目标的实现。这篇综述假设精神病和情绪障碍研究领域已经取得了足够的进展，可以对特定疾病的病因病理学提出生化假设，并以此为目标进行更有效的疾病修饰治疗。这意味着治疗精神病和情绪障碍的“一刀切”模式并不是一种可行的方法，但基于个体生物异常的定制治疗方案将为更有效的治疗铺平道路。在回顾临床和临床前文献时，本文讨论了情绪和精神障碍中最受关注的病理生理过程，从而为该领域的未来研究选择合适的生物标志物、开发生物标志物组、以及改进诊断和定制治疗方案以获得更好的治疗结果提供了框架。
Despite significant research efforts aimed at understanding the neurobiological underpinnings of mood (depression, bipolar disorder) and psychotic disorders, the diagnosis and evaluation of treatment of these disorders are still based solely on relatively subjective assessment of symptoms as well as psychometric evaluations. Therefore, biological markers aimed at improving the current classification of psychotic and mood-related disorders, and that will enable patients to be stratified on a biological basis into more homogeneous clinically distinct subgroups, are urgently needed. The attainment of this goal can be facilitated by identifying biomarkers that accurately reflect pathophysiologic processes in these disorders. This review postulates that the field of psychotic and mood disorder research has advanced sufficiently to develop biochemical hypotheses of the etiopathology of the particular illness and to target the same for more effective disease modifying therapy. This implies that a “one-size fits all” paradigm in the treatment of psychotic and mood disorders is not a viable approach, but that a customized regime based on individual biological abnormalities would pave the way forward to more effective treatment. In reviewing the clinical and preclinical literature, this paper discusses the most highly regarded pathophysiologic processes in mood and psychotic disorders, thereby providing a scaffold for the selection of suitable biomarkers for future studies in this field, to develope biomarker panels, as well as to improve diagnosis and to customize treatment regimens for better therapeutic outcomes.